Phase 3 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form.
- People of any sex assigned at birth.
Who may not be able to join:
- People whose blood sugar control levels (measured by a test called HbA1c) are at or above a certain threshold at the screening stage, as tested by the trial's central laboratory.
- People who have a personal history of type 1 or type 2 diabetes, either as reported by themselves or recorded in their medical history.
- People who have previously been treated with certain diabetes or weight-related medications, including GLP-1 receptor agonists, dual GLP-1/GIP receptor agonists, or amylin analogues, before the screening stage (confirm with trial site for a full list of affected medications).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Relative change in body weight
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.